Financials BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-10 pm EST			5-day change	1st Jan Change
187.50 ^USD	-9.69%		-8.99%	+3.96%

Dec. 10	BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets	CI
Dec. 05	BeiGene, Ltd. Presents at Citi's 2024 Global Healthcare Conference, Dec-05-2024 09:30 AM

Projected Income Statement: BeiGene, Ltd.

income-statement-evolution-chart BEIGENE-LTD

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	428.2	308.9	1,176	1,416	2,459	3,720	4,677	5,641
Change	-	-27.87%	280.83%	20.37%	73.65%	51.28%	25.74%	20.62%
EBITDA ¹	-941.3	-1,626	-1,392	-1,723	-1,120	-531.1	52.44	536.9
Change	-	72.73%	-14.37%	23.78%	-35.01%	52.59%	-	923.83%
EBIT ¹	-959.9	-1,658	-1,439	-1,790	-1,208	-631.7	-130.8	321.3
Change	-	72.69%	-13.21%	24.39%	-32.52%	47.7%	79.3%	-
Interest Paid ¹	9.131	1.998	-15.76	52.48	74.01	-16.92	-42.52	-63.54
Earnings before Tax (EBT) ¹	-943.6	-1,618	-1,439	-1,961	-825.8	-563.8	-72.88	464
Change	-	71.49%	-11.1%	36.32%	-57.89%	31.73%	87.07%	-
Net income ¹	-948.6	-1,597	-1,413	-2,004	-881.7	-594.3	-67.36	396.6
Change	-	68.34%	-11.49%	41.78%	-56%	32.6%	88.66%	-
Announcement Date	3/2/20	2/25/21	2/25/22	2/27/23	2/26/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3
Net sales ¹	56.89	52.06	65.64	91.08	100.1	605.9	150	206.4	214	306.6	341.6	387.6	380.1	447.8	595.3	781.3	634.4	751.7	929.2	1,002	1,041	1,072	1,118	1,163	1,206	1,241	1,267	1,293
Change	-	-8.5%	26.08%	38.77%	9.9%	505.27%	-75.24%	37.63%	3.65%	43.3%	11.4%	13.48%	-1.94%	17.81%	32.93%	31.25%	-18.8%	18.48%	23.62%	7.8%	3.9%	3%	4.31%	4%	3.73%	2.9%	2.08%	2.04%
EBITDA ¹	-	-	-	-	-477.1	79.8	-463.3	-450.1	-558.6	-426.7	-423.9	-422.2	-450.6	-351.2	-	-112.5	-565.3	-236.1	-82.23	-48.97	-210.2	-93.49	-74.51	-60.24	-57.87	74.22	100.1	114.2
Change	-	-	-	-	-	-	-	-2.84%	24.1%	-23.62%	-0.64%	-0.42%	6.74%	-22.05%	-100%	-	402.67%	-58.24%	-65.16%	-40.44%	-329.26%	55.53%	20.3%	19.15%	3.93%	-	34.93%	14.01%
EBIT ¹	-388	-373.8	-358.9	-440.1	-484.9	70.17	-474.8	-462.3	-571.7	-443.3	-439.4	-438.4	-468.6	-371.3	-318.7	-134	-589.1	-261.3	-107.2	-120.3	-137.6	-102.5	-67.73	-39.13	-31.87	27.08	53	67.03
Change	-	-3.68%	-3.98%	22.64%	10.17%	-	-	-2.64%	23.67%	-22.47%	-0.88%	-0.24%	6.9%	-20.78%	-14.15%	-57.97%	339.74%	-55.64%	-59%	12.23%	-14.4%	25.5%	33.93%	42.23%	18.54%	-	95.71%	26.46%
Charge d'intérêts	-0.438	6.69	1.108	-0.614	-5.186	-4.179	-4.866	-2.23	-4.482	10.07	11.43	-	18.22	-	-	26.65	16.27	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-380.3	-363.4	-337.8	-435	-482	61.86	-480.6	-433.1	-586.8	-421.2	-557.6	-551.2	-431	-336.9	-367.5	229.3	-350.8	-243.4	-105.9	-98.3	-73.29	-70.95	-28.25	7.621	17.43	-	-	-
Change	-	-4.46%	-7.04%	28.79%	10.79%	-	-	-9.88%	35.5%	-28.21%	32.36%	-1.14%	-21.82%	-21.82%	9.06%	-	-	-30.6%	-56.49%	-7.19%	25.44%	3.2%	60.18%	-	128.74%	-100%	-	-
Net income ¹	-388.1	-363.7	-335.2	-425.2	-472.7	66.5	-480.3	-413.9	-585.7	-434.3	-571.4	-557.6	-445.3	-348.4	-381.1	215.4	-367.6	-251.2	-120.4	-121.4	-91.22	-80.76	-37.02	-2.932	6.887	-	-	-
Change	-	-6.27%	-7.84%	26.86%	11.18%	-	-	-13.84%	41.51%	-25.85%	31.59%	-2.43%	-20.13%	-21.76%	9.39%	-	-	-31.67%	-52.06%	0.78%	24.83%	11.46%	54.16%	92.08%	-	-100%	-	-
Announcement Date	3/2/20	5/11/20	8/6/20	11/5/20	2/25/21	5/6/21	8/5/21	11/4/21	2/25/22	5/5/22	8/4/22	11/9/22	2/27/23	5/4/23	8/2/23	11/9/23	2/26/24	5/8/24	8/7/24	11/12/24	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2021 S2	2022 S2	2023 S1	2023 S2	2024 S1	2024 S2
Net sales ¹	420.4	606.4	1,043	-	1,681	2,037
Change	-	44.24%	72%	-100%	-	21.19%
EBITDA	-	-	-	-	-	-
Change	-	-	-	-	-	-
EBIT ¹	-	-907	-690	-	-368.5	-195
Change	-	-	-23.93%	-100%	-	47.08%
Charge d'intérêts	-	-	-	16.27	-	-
Earnings before Tax (EBT) ¹	-	-982.2	-704.4	-	-349.3	-167
Change	-	-	-28.28%	-100%	-	52.2%
Net income ¹	-999.5	-998.1	-729.6	-	-371.6	-217
Change	-	-0.14%	-26.9%	-100%	-	41.6%
Announcement Date	2/25/22	2/27/23	8/2/23	2/26/24	8/7/24	-

¹USD in Million

Estimates

Forecast Balance Sheet: BeiGene, Ltd.

balance-sheet-analysis-chart BEIGENE-LTD

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-742	-4,132	-3,746	-3,332	-2,297	-1,794	-1,816	-2,397
Change	-	-656.87%	-190.66%	-188.95%	-168.94%	-178.09%	-201.23%	-231.99%
Announcement Date	3/2/20	2/25/21	2/25/22	2/27/23	2/26/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: BeiGene, Ltd.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	89.61	117.5	262.9	325.4	561.9	389.9	317.6	340
Change	-	31.13%	123.77%	23.77%	72.66%	-30.62%	-18.54%	7.04%
Free Cash Flow (FCF) ¹	-839.9	-1,401	-1,562	-1,822	-1,719	-724.3	-188.1	324.3
Change	-	66.81%	11.47%	16.67%	-5.64%	-57.87%	-74.03%	-272.44%
Announcement Date	3/2/20	2/25/21	2/25/22	2/27/23	2/26/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: BeiGene, Ltd.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	-219.81%	-526.39%	-118.36%	-121.71%	-45.55%	-14.28%	1.12%	9.52%
EBIT Margin (%)	-224.16%	-536.69%	-122.31%	-126.4%	-49.12%	-16.98%	-2.8%	5.7%
EBT Margin (%)	-220.35%	-523.9%	-122.3%	-138.5%	-33.59%	-15.16%	-1.56%	8.23%
Net margin (%)	-221.53%	-517.01%	-120.15%	-141.52%	-35.86%	-15.98%	-1.44%	7.03%
FCF margin (%)	-196.14%	-453.57%	-132.76%	-128.68%	-69.93%	-19.47%	-4.02%	5.75%
FCF / Net Income (%)	88.54%	87.73%	110.49%	90.93%	195%	121.89%	279.21%	81.77%
Profitability
ROA	-49.13%	-44.28%	-19.84%	-26.87%	-14.47%	-10.11%	-1.93%	6.34%
ROE	-70.23%	-66.1%	-27.95%	-38.11%	-22.26%	-17.12%	-1.17%	12.32%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	20.93%	38.04%	22.35%	22.98%	22.85%	10.48%	6.79%	6.03%
CAPEX / EBITDA (%)	-9.52%	-7.23%	-18.89%	-18.88%	-50.17%	-73.41%	605.62%	63.32%
CAPEX / FCF (%)	-10.67%	-8.39%	-16.84%	-17.86%	-32.68%	-53.82%	-168.85%	104.82%
Items per share
Cash flow per share ¹	-12.49	-15.38	-14	-14.51	-11.09	2.418	2.101	7.516
Change	-	23.07%	-8.97%	3.68%	-23.59%	-121.8%	-13.11%	257.78%
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	14.77	46.35	67.28	42.5	33.89	30.24	31.85	40.16
Change	-	213.78%	45.15%	-36.83%	-20.27%	-10.76%	5.33%	26.06%
EPS ¹	-15.8	-19.13	-15.23	-19.43	-8.45	-5.573	-0.3985	4.547
Change	-	21.08%	-20.39%	27.58%	-56.51%	-34.05%	-92.85%	-1,241.17%
Nbr of stocks (in thousands)	61,136	90,924	102,770	103,859	104,578	106,246	106,246	106,246
Announcement Date	3/2/20	2/25/21	2/25/22	2/27/23	2/26/24	-	-	-